**The Big Picture**

MAPS’ FY 07-08 income was $1,698,454. Expenses were $1,446,618. MAPS had a $252,316 surplus, which will be spent on future projects requiring many millions of dollars. Assets at the end of FY 07-08 amounted to $1,041,011, of which $260,050 was restricted to various projects and $780,961 was unrestricted. For an historical comparison of FY 07-08 to previous years, see Chart 1 on page 5. For an overview of FY 07-08 income, assets, and expenses see Chart 2 on page 6.

Additional donations not reflected in MAPS’ income or expenses, amounting to about $77,000, were made directly to a Swiss non-profit, the Swiss Medical Association for Psycholytic Therapy (SAEPT), in support of MAPS-sponsored Swiss MDMA/PTSD and LSD/end-of-life anxiety studies.

**Income-$1,698,454**

MAPS’ FY 07-08 income was $1,698,454. Of that amount, $1,233,061 came from individuals and foundations donating $1000 or more, $193,689 came from individuals who donated less than $1000, $78,977 came from book, clothes and art sales, and $192,727 came from other sources such as interest, travel stipends, sublease on rental property, special event income, and Entheon Village/Burning Man registration fees. MAPS’ reported income doesn’t include invaluable donations of time by a sizable number of volunteers who assist us in a range of projects. Some volunteers help with our software and website, others from the pharmaceutical industry provide expertise in clinical research monitoring and data management, some lawyers donate legal services, and numerous other volunteers assist with basic operations.

MAPS donors who give under $1000 per year contribute about half of our operating expenses. The other half of our operating expenses and the bulk of our research and educational budgets come from larger donors. This combination of a few large and many small donors is the key to our success. When each donor gives what they can, be that $20 or $200,000, we have enough to fund our operations and our research and educational projects.

**Due to their small number and their generosity, I’d like to thank our roughly 20 major donors by name. Our two largest individual donors, Ashawna Hailey and John Gilmore, are both on MAPS’ Board of Directors. Ashawna donated $320,000, $20,000 of which was restricted to Erowid and John donated $175,000, $25,000 of which was restricted to Erowid. An anonymous donor gave $119,000, all for MDMA/PTSD research. David Bronner donated $100,949, most of it for our Israeli medical marijuana project. Robert Barnhart donated $97,704, of which $75,000 was for our Swiss LSD/end-of-life study and the rest unrestricted. Peter Lewis donated $96,101 in unrestricted funds. Wendy Grace donated $50,000, $35,000 unrestricted and $15,000 to the Women’s Visionary Congress and the Women’s Entheogen Fund. Annie Harrison donated $21,557 for the Women’s Visionary Congress. Kevin Herbert donated $19,378 to underwrite half of the publication of LSD Psychotherapy by Stan Grof and to support our Swiss LSD/end-of-life study. Michael Marcus donated an unrestricted $20,000. Richard Miller and Seth Hollub each donated $10,000, with Seth’s funds restricted to cluster headache research. Tim Butcher donated $9,000 for our US MDMA/PTSD study. Jo Crown donated $8,569 unrestricted. Ramez Naam donated $7,800 for Erowid. Richard Wolfe and Rene Ruiz each donated $6,000 unrestricted. John Buchanan donated $5000 to underwrite half the costs of the new edition of Stan Grof’s LSD Psychotherapy. June Blewitt donated $5,000 to our US MDMA/PTSD research, and an anonymous patron donated $5,000 for our Swiss LSD/end-of-life study. MAPS has also received donations from foundations and organizations. We received $50,000 from the Libra Foundation, $25,000 of which was for the US MDMA/PTSD study and $25,000 for operational expenses. The Robert Keller Foundation donated $50,000, all for our US MDMA/PTSD study. The Burning Man organization donated $20,000 for the Basura Sagrada Temple project, since MAPS was the fiscal sponsor for the builders of the Basura Sagrada Temple. The Marijuana Policy Project donated $6000 for Prof. Lyle Craker at UMass Amherst, for our effort to obtain a DEA license for a medical marijuana production facility.

**Donations to Allied Organizations on Behalf of MAPS-$77,000**

For tax benefits for our donors who live outside the US, MAPS is seeking to develop relationships with nonprofit organizations in the various countries in which we’re conducting research. These donations and expenditures don’t show up on MAPS’ books, but they support MAPS-sponsored projects.

MAPS donor and Swiss Citizen Vanja Palmers donated $60,000 directly to the Swiss account of SAEPT; $10,000 for our Swiss LSD/end-of-life anxiety study and $50,000 to our Swiss MDMA/PTSD study. Swiss citizen Fredi Muller donated 10,000 Swiss Francs to SAEPT and British citizen Amanda Fielding donated 5000 Euros to SAEPT, both for our Swiss LSD/end-of-life anxiety study.

**Assets-$1,041,010**

In FY 07-08, MAPS had $252,316 more in income than expenses. As a result, MAPS’ assets as of May 31, 2008 grew to $1,041,010. Of that amount, $260,050 was restricted to specific purposes and $780,961 was unrestricted. See Chart 3 on page 6 for a listing of the amounts of funds restricted to each project.

MAPS has never before had assets amounting to more than $1 million at the close of a fiscal year. This sum demonstrates the generosity of MAPS members and their willingness to entrust MAPS staff with their donations, and their hopes for medical use of psychedelics and marijuana. When compared to zero, $1 million is an incredible amount of money. When compared to the roughly $10 million that I estimate we’ll need to develop MDMA into a
prescription medicine for the treatment of PTSD, we’re not even close. Furthermore, we’re working to develop other psychedelics and marijuana into prescription medicines, and we need to retain a substantial portion of MAPS’ assets as an operating reserve.

**Expenses-$1,446,138**

MAPS FY 07-08 expenses were $1,446,138. Of that amount, $400,609 was for research projects, $136,220 was for core educational projects, and $319,332 for educational projects for organizations and events for which MAPS acted as a fiscal sponsor. MAPS’ Website and forum cost $22,543. An additional $236,639 was for project-related staff and office expenses, and $215,663 was for management and core operations. Fundraising expenses were $61,883. Product costs and royalties on art were $44,682. Finally, capital expenses were $10,864. We had refunds and adjustments of $2,297. See Chart 4 on page 7 for a detailed list of expenses. Each major research, educational, and staff salary expense item is discussed below.

**Research Projects-$ 406,609**

Conducting research is our top priority. The following research projects reflect our organizational priority of conducting strategic psychedelic-assisted psychotherapy and medical marijuana research and, where possible, conducting clinical trials under the US Food and Drug Administration and European Medicines Agency.

In order to present more information about MAPS’ expenditures, I will briefly go over each item. Chart 4 on page 7 will enable you to see all the items at a glance.

**US MDMA/PTSD Study-$235,843**

Our largest expenditure on research was for ongoing costs for MAPS’ pilot MDMA-assisted psychotherapy study, conducted in Charleston, South Carolina under the direction of Dr. Michael Mitroofer and Ann Mitroofer BSN. This study investigated MDMA-assisted psychotherapy in subjects with treatment-resistant Posttraumatic Stress Disorder (PTSD). The 21st and final subject completed the two-month follow-up in September 2008, concluding the study. Over the years, MAPS has spent about $1 million on this study. The results of this study are so promising that it was worth every penny. We’re now expanding our MDMA/PTSD research to new countries and therapeutic teams, testing different protocol modifications that will help us in the design of the Phase 3 studies. If other therapist teams can get results similar to the results obtained by Michael and Ann Mitroofer, we will have sufficient evidence to justify the prescription use of MDMA-assisted psychotherapy.

**Swiss MDMA/PTSD Study-$4,390**

This item is for ongoing costs related to Dr. Peter Oehen’s MAPS-sponsored MDMA/PTSD study, which has continued to enroll patients this year. This study is designed for 12 subjects and half have already been treated. The estimated completion date for this study is around September 2009. This study has been submitted to FDA under MAPS’ Investigational New Drug (IND) application for MDMA, in order to ensure that FDA will review the data generated by this study. The study actually cost substantially more than $4,390 in FY 07-08, but costs were paid out of the Swiss account of the Swiss Medical Association for Psycholytic Therapy (SAEPT), into which Swiss citizen and MAPS donor Vanja Palmers donated directly. The estimated total cost including funds spent directly from SAEPT was $55,000.

**Israel MDMA/PTSD Study-$11,020**

This item is for ongoing costs related to Dr. Moshe Kotler’s MAPS-sponsored MDMA/PTSD study, which has continued to enroll patients this year. This study is designed for 12 subjects and two have already been treated. The estimated completion date for this study is around December 2009. This study has been submitted to FDA under MAPS’ Investigational New Drug (IND) application for MDMA, in order to ensure that FDA will review the data generated by this study.

**Canada MDMA/PTSD Study-$1,715**

This item is for protocol development for a new MAPS-sponsored MDMA/PTSD study to take place in Vancouver, Canada, with co-therapists Ingrid Pacey MD (psychiatrist) and Psychologist Andrew Feldmar. A Canadian Institutional Review Board (IRB) has approved the study, with Health Canada approval still required. When we obtain full approval and start this study, it will be the first psychedelic research in Canada in about 35 years. This study is designed for 12 subjects.

**MDMA Therapist Training Program-$6,378**

MAPS is developing a training program for therapists who will hire to conduct our Phase 3 research into MDMA-assisted psychotherapy for PTSD. These costs are for training program development, which includes evaluating and learning from therapists currently conducting MDMA/PTSD studies for MAPS.

**MDMA Literature Review-$6,663**

MAPS research associate Ilsa Jerome, Ph.D. is responsible for keeping current on the state of the art of the world’s scientific, peer-reviewed literature on MDMA. She continued this ongoing review throughout FY 07-08. When applying to the FDA and Institutional Review Boards with a new protocol, it is necessary to have a comprehensive review of all factors related to risk.

**MDMA Research-$4,742**

These are general expenditures in support of our MDMA research efforts that benefit multiple MDMA projects.

**Swiss LSD/End-of-Life Anxiety Study-$6,400**

MAPS worked with Peter Gasser, MD, a Swiss psychiatrist, on the protocol development and approval process for a pilot study investigating the safety and efficacy of LSD-assisted psychotherapy in reducing anxiety and pain in patients with end-of-life diagnoses. The study gained approval and treated its first subject in this fiscal year. When completed, this will become the first study of the therapeutic use of LSD in over 35 years. Additional funds

<table>
<thead>
<tr>
<th>Fiscal Year</th>
<th>Income</th>
<th>Expenses</th>
<th>Assets</th>
</tr>
</thead>
<tbody>
<tr>
<td>2000/1</td>
<td>$937,581.00</td>
<td>$956,509.00</td>
<td>$349,134.00</td>
</tr>
<tr>
<td>2001/2</td>
<td>$775,945.00</td>
<td>$719,589.00</td>
<td>$404,401.00</td>
</tr>
<tr>
<td>2002/3</td>
<td>$596,583.00</td>
<td>$621,526.00</td>
<td>$379,403.00</td>
</tr>
<tr>
<td>2003/4</td>
<td>$812,540.15</td>
<td>$903,883.36</td>
<td>$670,152.95</td>
</tr>
<tr>
<td>2004/5</td>
<td>$1,035,837.00</td>
<td>$653,780.00</td>
<td>$761,486.00</td>
</tr>
<tr>
<td>2005/6</td>
<td>$1,156,017.76</td>
<td>$1,025,475.22</td>
<td>$783,522.99</td>
</tr>
<tr>
<td>2006/7</td>
<td>$1,285,493.05</td>
<td>$1,288,059.26</td>
<td>$788,694.34</td>
</tr>
<tr>
<td>2007/8</td>
<td>$1,698,453.95</td>
<td>$1,446,137.76</td>
<td>$1,041,010.53</td>
</tr>
</tbody>
</table>

amounting to an estimated $15,400 for study expenses that have been paid from the SAEPT account and are not reflected on MAPS’ books.

Psilocybin Cancer/Anxiety Study—$12,005

This item is for the protocol development and approval process for a study of psilocybin-assisted therapy with advanced-stage melanoma cancer patients with anxiety. Sameet Kumar, Ph.D. will conduct the study. The FDA has approved the protocol, but we’re still seeking an institution in Southern Florida willing to let the study take place there and have its IRB review the protocol.

Ibogaine Canada—$3,554

MAPS was sponsoring a study of the long-term effectiveness of ibogaine-assisted therapy in the treatment of opiate addiction. This study was located in Vancouver, Canada with patients treated at the Iboga Therapy House. Funds were used for enrollment and follow-up for five subjects. Unfortunately, the Iboga Therapy House shut its door for financial reasons and our study has ended prematurely. Fortunately, this study has led to another ibogaine outcome study in Mexico and helped introduce us to therapists in Vancouver with whom we’re working to start our Canadian MDMA/PTSD study.

Ibogaine Mexico—$1,308

MAPS is sponsoring a study of the long-term effectiveness of ibogaine-assisted therapy in the treatment of opiate addiction. This study is located in Mexico, with patients treated at the Ibogaine Association, and funds were used for protocol development, training, and approval.

Cluster Headache Protocol—Psilocybin—$26,914

MAPS donated $26,000 to Clusterbusters, a group of people who suffer from cluster headaches and have found psilocybin and LSD to be effective in treating their headaches. The donation was for the development of a protocol to evaluate psilocybin in the context of a clinical study.

Cluster Headache LSA Study—$3,251

MAPS funded Dr. Andrew Sewell to gather information from cluster headache sufferers who had used morning glory seeds that contained lysergic acid amide (LSA). This is important because these seeds are relatively easy to obtain, while it will take many years to obtain legal approval for LSD or psilocybin for cluster headaches.

Cluster Headache LSD Protocol—$1,158

MAPS’ Research and Information Specialist Ilsa Jerome, PhD worked on protocol development for a study of LSD in treating cluster headaches. The study will be funded by Clusterbusters and will probably take place at McLean Hospital, Harvard Medical School.
Our largest expenditure on research was for ongoing costs for MAPS' pilot MDMA-assisted psychotherapy study, conducted in Charleston, South Carolina under the direction of Dr. Michael Mithoefer and Ann Mithoefer BSN.

This study investigated MDMA-assisted psychotherapy in subjects with treatment-resistant Posttraumatic Stress Disorder (PTSD)... Over the years, MAPS has spent about $1 million on this study. The results of this study are so promising that it was worth every penny.
Occasionally, MAPS acts as the fiscal sponsor for externally-generated educational projects that fit into our mission. If a project that fits in our general mission statement is able to independently secure funding and staffing, MAPS is able to provide oversight and tax-exempt status to the project.

<table>
<thead>
<tr>
<th>RESEARCH PROJECTS As of 5/31/2008</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>MP-1 MDMA PTSD-US</td>
<td>$235,843</td>
</tr>
<tr>
<td>MP-2 MDMA PTSD-Swiss</td>
<td>$4,390</td>
</tr>
<tr>
<td>MP-3 MDMA PTSD-Israel</td>
<td>$11,020</td>
</tr>
<tr>
<td>MP-4 MDMA/PTSD-Canada</td>
<td>$1,715</td>
</tr>
<tr>
<td>MDMA Therapist Training</td>
<td>$6,378</td>
</tr>
<tr>
<td>MDMA Literature Review</td>
<td>$6,663</td>
</tr>
<tr>
<td>MDMA Research</td>
<td>$4,742</td>
</tr>
<tr>
<td>LDA-1 LSD Swiss End-of-Life Study</td>
<td>$6,400</td>
</tr>
<tr>
<td>Psilocybin/Cancer Anxiety Study</td>
<td>$12,005</td>
</tr>
<tr>
<td>Ibogaine Canada</td>
<td>$3,554</td>
</tr>
<tr>
<td>Ibogaine Mexico</td>
<td>$1,308</td>
</tr>
<tr>
<td>Cluster Headache Study</td>
<td>$26,914</td>
</tr>
<tr>
<td>LSA Clusterheadache</td>
<td>$3,251</td>
</tr>
<tr>
<td>LSD Cluster Headache Protocol</td>
<td>$1,158</td>
</tr>
<tr>
<td>MJ Production Facility/UMass Amherst</td>
<td>$6,828</td>
</tr>
<tr>
<td>MJ Vaporizer Study</td>
<td>$1,500</td>
</tr>
<tr>
<td>Dr. Abrams MMJ Study SF</td>
<td>$167</td>
</tr>
<tr>
<td>Vancouver Island Compassion Study</td>
<td>$8,000</td>
</tr>
<tr>
<td>Israel Medical Marijuana Farm</td>
<td>$58,774</td>
</tr>
<tr>
<td>TOTAL RESEARCH PROJECTS</td>
<td>$400,609</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CORE EDUCATIONAL PROJECTS As of 5/31/2008</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>DEA/UMASS Cong. Sign on Letter</td>
<td>$61,369</td>
</tr>
<tr>
<td>CME Project</td>
<td>$1,056</td>
</tr>
<tr>
<td>World Psychedelic Forum 2008</td>
<td>$18,214</td>
</tr>
<tr>
<td>Burning Man Sanctuary</td>
<td>$4,154</td>
</tr>
<tr>
<td>Information</td>
<td>$618</td>
</tr>
<tr>
<td>Conference-DPA</td>
<td>$2,793</td>
</tr>
<tr>
<td>WWDPE (Difficult Trip Video)</td>
<td>$125</td>
</tr>
<tr>
<td>MAPS Bulletin</td>
<td>$47,891</td>
</tr>
<tr>
<td>TOTAL CORE EDUCATIONAL PROJECTS</td>
<td>$136,220</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EDUCATIONAL PROJECTS FISCAL SPONSORSHIP As of 5/31/2008</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Burning Man 2008</td>
<td>$2,254</td>
</tr>
<tr>
<td>Burning Man 2007</td>
<td>$128,273</td>
</tr>
<tr>
<td>Basura Sagrada (BM Temple)</td>
<td>$18,764</td>
</tr>
<tr>
<td>Conference-Peru</td>
<td>$12,879</td>
</tr>
<tr>
<td>S.A.F.E.R./UC Boulder Colorado State</td>
<td>$15,000</td>
</tr>
<tr>
<td>Womens Visionary Congress</td>
<td>$50,502</td>
</tr>
<tr>
<td>Women’s Alliance for Medical Marijuana (WAMM)</td>
<td>$9,300</td>
</tr>
<tr>
<td>Website EROWID</td>
<td>$82,359</td>
</tr>
<tr>
<td>TOTAL EDUCATIONAL PROJECTS</td>
<td>$319,332</td>
</tr>
<tr>
<td>TOTAL EDUCATIONAL PROJECTS FISCAL SPONSORSHIPS</td>
<td></td>
</tr>
<tr>
<td>TOTAL EDUCATIONAL PROJECTS BOTH INT. &amp; EXT</td>
<td>$455,552</td>
</tr>
</tbody>
</table>
Marijuana Production Facility/UMass Amherst-$6,628

MAPS donated $6,000 to UMass Amherst Professor Lyle Craker to compensate him for his time working to reverse the DEA's refusal to grant him a license for a MAPS-sponsored medical marijuana production facility. MAPS also spent $828 on expenses for a press conference to draw attention to the recommendation of DEA Administrative Law Judge Bittner that DEA should issue Prof. Craker a license, since she found that it would be in the public interest to end the government's monopoly on the supply of marijuana legal for use in federally-approved research.

Marijuana Vaporizer Study-$1500

MAPS paid Chemic Labs for the development of a protocol to submit to NIDA seeking to purchase 10 grams of marijuana so we could continue our research into the constituents of the vapors produced by the Volcano vaporizer. We have now been trying for 5 years without success to purchase 10 grams of marijuana from NIDA! This obstruction of our vaporizer research is clear evidence of why it would be in the public interest for Prof. Craker to be issued a DEA license for a MAPS-sponsored medical marijuana production facility.

Dr. Donald Abrams Marijuana/Pain/Opiates Study-$167

As far as we can tell, Dr. Abrams is currently the only researcher in the US who is actively evaluating the medical use of marijuana in a patient population. MAPS has donated staff time and resources to assist with travel and lodging for patients in Dr. Abrams' study of medical marijuana in conjunction with pain medications. MAPS has also agreed to help find the remaining patients for this study. These costs are for the early stages of this project, which is primarily taking place in FY 08-09.

Vancouver Island Medical Marijuana

Philippe Lucas, founder of the Vancouver Island Compassion Club, received an $8000 grant, donated to MAPS by David Bronner, to study the patients who come to his club. One aim of the study is to see if certain strains of marijuana are more effective in certain clinical conditions.

Israel Medical Marijuana

Production Facility-$58,774

The Israeli Ministry of Health has established a policy whereby physicians whose patients have any of a certain limited number of clinical conditions can apply to the Ministry requesting that their patient receive a license to use marijuana legally. Since there was no legal supply of marijuana in Israel, the Ministry of Health decided to issue several licenses to produce marijuana for Ministry-approved patients. The license does not permit the producer to sell the marijuana, thus it requires that the marijuana be given away for free. The producers must obtain donations to cover their costs. David Bronner donated funds to MAPS to help subsidize the costs of one grower. Over time, as more patients are approved and obtain medical benefits, we think the Ministry may reconsider the policy of free distribution and permit sales which would then be a sustainable model.

DETAILED EXPENSE REPORTS

EDUCATION-$455,552

MAPS' mission includes both research into the beneficial uses of psychedelic and marijuana and educating the public honestly about the risks and benefits of these drugs. Since there is so much misinformation about the risks of psychedelics and marijuana, and so much denial about any benefits, our educational mission is as critical as our research mission. We've undertaken quite a few educational projects, which I will describe below. These educational projects will be divided into two categories, those that are part of MAPS' core activities and those conducted by other organizations for which we are acting as fiscal sponsor and whose activities are aligned with MAPS' mission.

MAPS' Core Educational Projects-$136,220

DEA UMass Amherst/Congressional Sign-On Letter-$61,369

On February 12, 2007, DEA Administrative Law Judge Mary Ellen Bittner issued her findings of fact and recommendation in the case of Prof. Lyle Craker. ALJ Bittner recommended that DEA issue a license to Prof. Craker for a MAPS-sponsored medical marijuana production facility, which would end the federal monopoly on the supply of marijuana legal for research. The licensing of Prof. Craker would catalyze a serious drug development research program, which is what DEA is seeking to prevent. DEA must issue a final ruling in response to ALJ Bittner's recommendation, but there is no timetable within which DEA must act.

MAPS initiated a major effort to educate members of the US House of Representatives about ALJ Bittner's recommendation. We obtained signatures of 45 Congressional Representatives on a letter to DEA urging it to accept ALJ Bittner's recommendation. We also obtained written support from Senators Kennedy and Kerry, who sent a letter to DEA urging it to accept ALJ Bittner's recommendation. Considering how close Senators Kennedy and Kerry are to President-elect Obama, there is a reasonable chance that DEA under an Obama Administration will put science first and issue Prof. Craker his license. If that happens, the controversy over the medical use of marijuana will be decided by the outcome of FDA-sanctioned research. Funds for our Congressional educational campaign were donated to MAPS by board member John Gilmore.

Continuing Medical Education (CME) Project-$1,056

MAPS is in the early planning stages of organizing a Continuing Medical Education (CME) conference for psychiatrists, psychologists, and nurses about the latest findings from clinical research with psychedelics. This will be an international conference that we'll hold in the San
Working with Difficult Psychedelic

information about MAPS.

staff attending the Drug Policy Alliance conference in New

Drug Policy Alliance Conference-$2,793

that MAPS staff purchase for their own education.

Information-$618

contrast, are criminalized in the US.

acceptance of the value of harm reduction services that, in

was made possible by the Portuguese law enforcement’s

comprehensive harm reduction services I’ve ever seen. This

43) and, consequently, I witnessed Boom provide the most

part of the mission of the Rangers. Our goal was to create a

were able to witness the providing of such services become

might leave Burning Man in a more fragile condition than

at Burning Man who were having difficult psychedelic

experiences, thereby reducing the number of people who

were having difficult psychedelic experiences, thereby reducing the number of people who

might leave Burning Man in a more fragile condition than

when they arrived. This was deeply satisfying work and we

were able to witness the providing of such services become

part of the mission of the Rangers. Our goal was to create a

model program that could be adopted by festival organizers

all over the world. Our work at Burning Man brought us to

the attention of the organizers of the Boom Festival in Por-

tugal. We have worked closely with Boom (see article page

Temple Project-$18,764

One of the causes of the complete worldwide suppres-

sion of psychedelic research starting in the early seventies

was fear associated with the non-medical use of psyche-

delics—which in some cases had tragic outcomes. As MAPS

has been successful in helping to establish a renaissance in

psychedelic research, we’ve realized the importance of try-

ing to do what we can to minimize the chances of another

backlash. We decided to assist the Burning Man organiza-

tion’s Black Rock Rangers in offering support to people

at Burning Man who were having difficult psychedelic

experiences, thereby reducing the number of people who

might leave Burning Man in a more fragile condition than

when they arrived. This was deeply satisfying work and we

were able to witness the providing of such services become

part of the mission of the Rangers. Our goal was to create a

model program that could be adopted by festival organizers

all over the world. Our work at Burning Man brought us to

the attention of the organizers of the Boom Festival in Por-
tugal. We have worked closely with Boom (see article page

43) and, consequently, I witnessed Boom provide the most

comprehensive harm reduction services I’ve ever seen. This

was made possible by the Portuguese law enforcement’s

acceptance of the value of harm reduction services that, in

contrast, are criminalized in the US.

Information-$618

This category of expenses is for educational materials

that MAPS staff purchase for their own education.

Drug Policy Alliance Conference-$2,793

This category is for expenses associated with MAPS

staff attending the Drug Policy Alliance conference in New

Orleans in December 2007, where we set up a table with

information about MAPS.

Working with Difficult Psychedelic

Experiences Video-$125

MAPS has created an educational video as part of our
efforts to prevent a backlash against psychedelic research
due to tragedies caused by people having difficult psyche-
delic experiences that they are not prepared to handle. Our
video presents information explaining how people can
help a friend if their friend is having a difficult psychedelic
experience. We created the video in prior fiscal years and
these expenditures were for preparing to create a newer
version, which took place in this current fiscal year.

MAPS Bulletin-$47,891

We use our Bulletin as a key educational tool. We
take special care to make the Bulletin a magazine that
people can proudly show to others. Bulletin costs have
been partially subsidized by using the color covers as an
opportunity to display art for sale through the MAPS store.
The Bulletin comes out 3 times a year and focuses mostly
on articles about MAPS’ various projects with occasional
special themed issues related in some way to psychedelics.
Our next themed issue, to come out in early 2009, is about
psychedelics and ecology

Education Projects for which MAPS

was Fiscal Sponsor-$319,332

Occasionally, MAPS acts as the fiscal sponsor for
externally-generated educational projects that fit into our
mission. If a project that fits in our general mission state-
ment is able to independently secure funding and staffing,
MAPS is able to provide oversight and tax-exempt status to
the project. The following categories are projects for which
MAPS acted as a fiscal sponsor.

Burning Man 2008-$2,254

These are early expenses for Entheon Village 2008, for
which MAPS once again handled the finances. As in years
before, expenses were covered by registration fees.

Burning Man 2007-$128,273

MAPS handled funds for Entheon Village 2007, which
we first helped to create at Burning Man 2006, where we
held MAPS’ 20th Anniversary. Expenses of Entheon Vil-
lage were covered by registration fees, for which people did
not receive tax receipts since their fees were for services
provided and were not donations. MAPS organized a lecture
series about psychedelic research and culture as part of
our educational mission. Participation in Entheon Village
helped MAPS fulfill our community outreach goals.

Burning Man Basura Sagrada

Temple Project-$18,764

MAPS served as fiscal sponsor for a team of artists
who built, and then burned, the Temple structure at Burn-
ing Man 2008. The Temple structure at Burning Man is a
place where people traditionally reflect on loved ones who
have died and is a meditative location that offers people
the opportunity to experience and express somber and
serious emotions—in contrast to the often carnival-like
mood elsewhere at Burning Man. The Temple structure
offers people a supportive place to experience complex
emotions and therefore adds an important, grounded
“harm reduction” element that, in combination with the
Sanctuary space, makes Burning Man a more psychologically balanced and healthy environment.

**Ayahuasca Conference in Peru-$12,879**

MAPS helped process registration fees for Alan Shoemaker, who organized the Amazonian Shamanism conference in Peru. People who paid registration fees did not receive tax receipts since they received services for their funds, which weren’t donations.

**SAFER/UC Boulder-$15,000**

These expenses are for educational efforts of SAFER, an organization that works with college students to teach them the relative dangers of alcohol as compared to other drugs. MAPS received a grant from Peter Lewis for this project in a prior fiscal year.

**Women’s Visionary Congress and Women’s Entheogen Fund-$50,502**

Organized by Annie Harrison, MAPS was a fiscal sponsor for the first Women’s Visionary Congress, which took place in the summer of 2007. The conference sought to provide a gathering place for women in the psychedelic movement, providing them with networking and speaking opportunities that are frequently absent or minimal at other psychedelic-related conferences. In preparation for the 2008 Women’s Visionary Congress, Annie Harrison created a new non-profit to sponsor the event.

MAPS also fiscally sponsored the $15,000 Women’s Entheogen Fund, which supported women who made significant contributions to the psychedelic movement. Annie Harrison and advisors determined allocations to Kat Harrison for $10,000 and the remainder went toward Valerie Mojeiko’s tuition at California Institute of Integral Studies.

**Women’s Alliance for Medical Marijuana Grant (WAMM)-$9,300**

Valerie Corral co-founded WAMM. She has been involved in litigation with DEA about her medical marijuana cooperative production facility. This grant from MAPS was for her public education efforts.

**Erowid Website-$82,359**

MAPS has served as fiscal sponsor for Erowid since 1999. Erowid is the most popular website offering information about a wide range of drugs, visited by about 50,000 unique visitors per day. Erowid has now obtained its own non-profit status and MAPS is no longer needed as a fiscal sponsor. Assisting Erowid was a special pleasure since the founders of Erowid, Earth and Fire, and I were college friends at New College of Florida.

**Detailed Expense Report–Staff Salaries and Benefits–$253,786**

All of our groundbreaking research would not be possible without our dedicated core staff. Our main office, located in Santa Cruz, currently employs three full-time staff, one three-quarters-time employee, one unpaid intern, one seasonal part-time employee, and occasional temporary employees on a project basis throughout the year.

MAPS strives to provide a fair and competitive salary and to offer a basic benefit package including healthcare and dental insurance.

The gross salary for core staff in the Santa Cruz office in FY 07-08 was $150,433, with benefits costing MAPS $43,353. Salary expenses are distributed across the projects to which staff are assigned. In addition, as MAPS President, I earned a total salary of $60,000 per year, and received no health care or other benefits (other than the tremendous satisfaction of working at MAPS). See Chart 5 on page 7.

**Conclusion**

The partnership between MAPS members, MAPS staff and MAPS-sponsored researchers has already generated powerful but preliminary evidence that MDMA-assisted psychotherapy has remarkably therapeutic potential in the treatment of PTSD. After 22 years of struggle, we’ve barely scratched the surface of the potential of psychedelic medicines. As for marijuana, we’re still being blocked from sponsoring drug development studies, though that may change for the better under an Obama Administration. The sums of money that we will be needing for research will run into the many millions, and we have a decade at least ahead of us just following up on the projects we have already started. We are working diligently to enhance our scientific, therapeutic, organizational, management, accounting, and communications systems, so that we can be prepared for our inevitable growth. With each successful step we take, the distant dream seems a little closer. While the challenges seem to progressively become a little harder, our skills and experience are growing to meet them.

MAPS has flourished in large part because we have built long-term relationships with our members/donors. What we are aiming to accomplish has already taken several decades and could easily take decades more. One donor has left to MAPS in his will a remainder interest in a home worth well over $1 million that we will receive in 30 years or so. That is too far ahead to have any practical benefit for the immediate future, but it is real enough to help us focus on building an organization that will outlast its founder (me). We have made our share of mistakes but we have demonstrated that we can learn from them. We respect the fears and concerns of our culture, but think the proverbial baby has been thrown out with the bathwater. We are vigilant not to move so quickly that we catalyze a backlash, but we understand the need to respond to the “fierce urgency of now.”

In these turbulent times, working together to develop tools of healing and spirituality is more important than ever. As a teenager I was (and remain) inspired by Tolkien who wrote, “This quest may be attempted by the weak with as much hope as the strong. Yet such is oft the course of deeds that move the wheels of the world: small hands do them because they must, while the eyes of the great are elsewhere.”